|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SHISA2 |
Gene summary for SHISA2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SHISA2 | Gene ID | 387914 |
| Gene name | shisa family member 2 | |
| Gene Alias | C13orf13 | |
| Cytomap | 13q12.13 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q6UWI4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 387914 | SHISA2 | GSM4909293 | Human | Breast | IDC | 1.23e-25 | 4.77e-01 | 0.1581 |
| 387914 | SHISA2 | GSM4909297 | Human | Breast | IDC | 7.28e-14 | 5.43e-01 | 0.1517 |
| 387914 | SHISA2 | GSM4909298 | Human | Breast | IDC | 6.52e-12 | 3.29e-01 | 0.1551 |
| 387914 | SHISA2 | GSM4909305 | Human | Breast | IDC | 1.44e-05 | 3.33e-01 | 0.0436 |
| 387914 | SHISA2 | GSM4909306 | Human | Breast | IDC | 3.70e-10 | 3.70e-01 | 0.1564 |
| 387914 | SHISA2 | GSM4909317 | Human | Breast | IDC | 6.38e-24 | 6.62e-01 | 0.1355 |
| 387914 | SHISA2 | P2T-E | Human | Esophagus | ESCC | 6.62e-20 | 4.17e-01 | 0.1177 |
| 387914 | SHISA2 | P8T-E | Human | Esophagus | ESCC | 3.50e-02 | 9.53e-02 | 0.0889 |
| 387914 | SHISA2 | P10T-E | Human | Esophagus | ESCC | 2.55e-08 | 2.38e-01 | 0.116 |
| 387914 | SHISA2 | P12T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.43e-01 | 0.1122 |
| 387914 | SHISA2 | P16T-E | Human | Esophagus | ESCC | 9.11e-40 | 9.08e-01 | 0.1153 |
| 387914 | SHISA2 | P22T-E | Human | Esophagus | ESCC | 3.60e-13 | 2.75e-01 | 0.1236 |
| 387914 | SHISA2 | P26T-E | Human | Esophagus | ESCC | 1.85e-18 | 3.86e-01 | 0.1276 |
| 387914 | SHISA2 | P30T-E | Human | Esophagus | ESCC | 5.16e-03 | 3.11e-01 | 0.137 |
| 387914 | SHISA2 | P32T-E | Human | Esophagus | ESCC | 3.75e-03 | 8.35e-02 | 0.1666 |
| 387914 | SHISA2 | P37T-E | Human | Esophagus | ESCC | 1.47e-04 | 1.64e-01 | 0.1371 |
| 387914 | SHISA2 | P48T-E | Human | Esophagus | ESCC | 2.65e-06 | 3.10e-01 | 0.0959 |
| 387914 | SHISA2 | P52T-E | Human | Esophagus | ESCC | 6.64e-10 | 4.50e-01 | 0.1555 |
| 387914 | SHISA2 | P56T-E | Human | Esophagus | ESCC | 6.45e-09 | 1.91e+00 | 0.1613 |
| 387914 | SHISA2 | P61T-E | Human | Esophagus | ESCC | 3.24e-05 | 2.56e-01 | 0.099 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:003011117 | Esophagus | ESCC | regulation of Wnt signaling pathway | 194/8552 | 328/18723 | 5.39e-07 | 7.14e-06 | 194 |
| GO:00301788 | Esophagus | ESCC | negative regulation of Wnt signaling pathway | 97/8552 | 170/18723 | 1.81e-03 | 8.31e-03 | 97 |
| GO:001605510 | Oral cavity | OSCC | Wnt signaling pathway | 227/7305 | 444/18723 | 1.10e-07 | 1.87e-06 | 227 |
| GO:019873810 | Oral cavity | OSCC | cell-cell signaling by wnt | 227/7305 | 446/18723 | 1.75e-07 | 2.86e-06 | 227 |
| GO:003011110 | Oral cavity | OSCC | regulation of Wnt signaling pathway | 165/7305 | 328/18723 | 1.87e-05 | 1.80e-04 | 165 |
| GO:001605520 | Thyroid | HT | Wnt signaling pathway | 48/1272 | 444/18723 | 9.68e-04 | 9.93e-03 | 48 |
| GO:019873820 | Thyroid | HT | cell-cell signaling by wnt | 48/1272 | 446/18723 | 1.07e-03 | 1.07e-02 | 48 |
| GO:00902874 | Thyroid | HT | regulation of cellular response to growth factor stimulus | 33/1272 | 304/18723 | 5.25e-03 | 3.50e-02 | 33 |
| GO:003011120 | Thyroid | HT | regulation of Wnt signaling pathway | 35/1272 | 328/18723 | 5.41e-03 | 3.58e-02 | 35 |
| GO:0016055110 | Thyroid | PTC | Wnt signaling pathway | 217/5968 | 444/18723 | 3.71e-14 | 2.30e-12 | 217 |
| GO:0198738110 | Thyroid | PTC | cell-cell signaling by wnt | 217/5968 | 446/18723 | 6.68e-14 | 3.73e-12 | 217 |
| GO:0030111110 | Thyroid | PTC | regulation of Wnt signaling pathway | 163/5968 | 328/18723 | 1.05e-11 | 4.29e-10 | 163 |
| GO:003017810 | Thyroid | PTC | negative regulation of Wnt signaling pathway | 74/5968 | 170/18723 | 8.99e-04 | 5.48e-03 | 74 |
| GO:009028712 | Thyroid | PTC | regulation of cellular response to growth factor stimulus | 120/5968 | 304/18723 | 2.87e-03 | 1.42e-02 | 120 |
| GO:001605525 | Thyroid | ATC | Wnt signaling pathway | 234/6293 | 444/18723 | 4.64e-17 | 4.31e-15 | 234 |
| GO:019873825 | Thyroid | ATC | cell-cell signaling by wnt | 234/6293 | 446/18723 | 9.26e-17 | 8.25e-15 | 234 |
| GO:003011125 | Thyroid | ATC | regulation of Wnt signaling pathway | 177/6293 | 328/18723 | 1.83e-14 | 1.05e-12 | 177 |
| GO:009028721 | Thyroid | ATC | regulation of cellular response to growth factor stimulus | 140/6293 | 304/18723 | 3.91e-06 | 4.33e-05 | 140 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SHISA2 | insertion | In_Frame_Ins | novel | c.526_527insATGTTTCATCCAGGGTATCATTGATTTATGATGGAAAAC | p.Ser176delinsTyrValSerSerArgValSerLeuIleTyrAspGlyLysPro | p.S176delinsYVSSRVSLIYDGKP | Q6UWI4 | protein_coding | TCGA-AN-A0FY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SHISA2 | SNV | Missense_Mutation | c.368N>T | p.Ser123Phe | p.S123F | Q6UWI4 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
| SHISA2 | SNV | Missense_Mutation | rs779132447 | c.379N>A | p.Ala127Thr | p.A127T | Q6UWI4 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-A6-2681-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| SHISA2 | SNV | Missense_Mutation | c.649T>C | p.Tyr217His | p.Y217H | Q6UWI4 | protein_coding | tolerated(0.11) | probably_damaging(0.958) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| SHISA2 | SNV | Missense_Mutation | c.377N>A | p.Val126Asp | p.V126D | Q6UWI4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SHISA2 | deletion | Frame_Shift_Del | c.495delN | p.Met166Ter | p.M166* | Q6UWI4 | protein_coding | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |||
| SHISA2 | SNV | Missense_Mutation | novel | c.605N>T | p.Ser202Leu | p.S202L | Q6UWI4 | protein_coding | deleterious(0.02) | possibly_damaging(0.578) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| SHISA2 | SNV | Missense_Mutation | rs372812470 | c.590N>T | p.Ala197Val | p.A197V | Q6UWI4 | protein_coding | tolerated(0.16) | benign(0.202) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SHISA2 | SNV | Missense_Mutation | rs766262628 | c.752N>T | p.Thr251Met | p.T251M | Q6UWI4 | protein_coding | deleterious(0.02) | benign(0.168) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SHISA2 | SNV | Missense_Mutation | c.406N>T | p.Ala136Ser | p.A136S | Q6UWI4 | protein_coding | tolerated(0.08) | probably_damaging(0.997) | TCGA-AP-A1DO-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |